DISCOVER The Oral Solid Dose Facility

This best-in-class facility in Research Triangle Park is a small, but robust, hub of activity within the Global Manufacturing organization. It serves as a prime example of Biogen Idec's relentless commitment to meet patient demand through continuous investment in manufacturing infrastructure.



The talented team of more than 90 employees at the OSD facility also apply their vast knowledge and expertise to the production of Eisai medicines, serving as contract manufacturers for several small molecule therapies, including:

- Lunesta for insomnia (market: Japan)
- Banzel for epilepsy (markets: U.S. and Canada)
- Aciphex for acid reflux (market: U.S.)
- Aricept for Alzheimer's disease (market: U.S.)

Biogen Idec and Eisai employees have formed a true partnership – sharing resources, facilities and communal lunch rooms – to make this unique and innovative manufacturing enterprise a model for success.

Facility Capabilities

Step inside this small molecule manufacturing facility and you will see granulators, blenders and machines for compression and encapsulation – all the ingredients and equipment used to make millions of tablets and capsules.

The OSD manufacturing process involves several critical activities to ensure a quality tablet or capsule, such as precise measuring and weighing of dry ingredients; wetting them for proper adhesion; milling and blending the

Facility Overview

The Oral Solid Dose (OSD) facility is the only Biogen Idec site that manufactures small molecule therapies – synthetically produced medicine delivered in the form of capsules and tablets. TECFIDERA, Biogen Idec's premier small molecule therapy, is the leading oral treatment for relapsing MS. The OSD facility began manufacturing TECFIDERA in 2014 after retrofitting the Eisai plant with new equipment and partnering with Eisai to share manufacturing space. **FAST FACT**

4.4 million TECFIDERA microtablets are produced per hour by the tablet press at the OSD facility

TECFIDERA production is currently in full swing at the OSD site as the new equipment is validated in preparation for FDA licensure – anticipated in the spring of 2015. Until licensure occurs, patients will receive TECFIDERA produced by contract manufacturers in Europe.

FAST FACT

Biogen Idec and Eisai employees share the same facility, thereby enhancing the level of partnership and cooperation



mixture, compressing it into the proper shape; applying a protective coating to the tablets; and placing the appropriate quantity of tablets into a capsule.

Small molecule production also requires world-class analytics and quality assurance to ensure the therapies have the proper chemical and physical characteristics to survive the production process while retaining optimal purity and efficacy.

FAST FACT

A batch of TECFIDERA treats 1,096 MS patients each year and the average cycle time for a batch is 35 days – best-in-class

.

The following seven steps ensure the purity, safety and efficacy of each and every pill produced at the OSD facility:

Dispensing -

Blending

F

Fluid BedDrying ofGranulation -moves warm airthrough the wetgranulation toremove thewater or solventto ensure theblend is readyfor the nextstep.


Tablet

involves prepping and weighing the active and inactive ingredients that make up the tablets and capsules.



and Milling – ensures consistency of the active ingredients.

the active ingredients. Milling grinds the particles to achieve the desired size while blending combines these particles to form a homogenous mixture.





Compression – tablets begin to take shape during this step,

which involves

feeding the

blend into a

pressure to

press, applying

form the tablets,

and de-dusting

them to remove

excess powder.

Coating – sprays a solution onto the tablets to enhance their flavor, appearance and efficacy; and to promote optimal absorption and to prevent stomach irritation.



- places certain formulations into capsule shells made of gelatin or similar digestible materials to ensure they are firm enough to hold the ingredients and maintain their stability.



FAST FACT

The OSD facility has produced 150-plus batches with a very high success rate – 97 percent of product manufactured will be suitable for release to the market



DISCOVER Biogen Idec Global Manufacturing

biogen idec.